Pharma CEOs face congressional showdown over pricing

25 February 2019

Six chief executives of global pharma companies are due to face questions from senior US senators on Tuesday, as lawmakers from both legislative chambers progress inquiries into the industry’s pricing practices.

The CEOs of Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE), Merck & Co (NYSE: MRK), AstraZeneca (LSE: AZN), AbbVie (NYSE: ABBV) and Sanofi (Euronext: SAN) will be joined by an executive president from Johnson & Johnson (NYSE: JNJ) to answer questions in the US Senate Finance Committee.

The committee investigation is led by Chairman Charles Grassley, with ranking member Ron Wyden due to play a prominent role in the inquiry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK